Dual Chamber Therapeutic Ledger Tracking for Mix-Up Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tracking systems for personalized patient therapeutics are prone to mix-ups during manufacturing and administration, posing risks of adverse reactions, treatment failure, and exposure to diseases.
Innovation Solution
A database and tracking engine utilizing a distributed ledger system to link patient information with drug administration, ensuring secure and accurate tracking of personalized therapeutics through a blockchain or notarized ledger, including manufacturing, shipping, and administration data.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If extrinsic labeling (bar codes, patient names) is used to identify patient therapeutics, then the system is simple to implement, but mix-ups and mislabeling can occur during manufacturing and administration
Solution Approach 1:
The patent replaces mechanical/extrinsic labeling systems (bar codes, handwritten labels) with an intrinsic molecular identification system. Each patient therapeutic is tagged with a unique molecular sequence that serves as its identity, eliminating reliance on external labels that can be misapplied or misread. This substitution fundamentally changes the identification mechanism from physical labels to molecular signatures.
Solution Approach 2:
The patent creates a digital copy of the therapeutic's molecular identity in a blockchain ledger. The molecular sequence serves as the original, and its digital representation in the distributed ledger serves as an immutable copy that tracks the therapeutic throughout the supply chain. This copying mechanism ensures that the identity information is preserved accurately without relying on physical labels.
2Reliability
If manual processing is used to handle patient therapeutics, then equipment complexity is reduced, but the risk of human error and mix-ups increases
Solution Approach 1:
The patent implements a feedback mechanism where the molecular sequence of each therapeutic is automatically read and verified at critical points in the workflow. The system compares the molecular identity against the blockchain ledger to confirm proper handling and transfer, providing automatic feedback that prevents erroneous actions without requiring manual verification steps.
Solution Approach 2:
The patient therapeutics essentially identify themselves through their inherent molecular sequences. The molecular tag passively carries identification information that can be automatically detected by scanning devices, eliminating the need for human operators to manually label, track, or verify therapeutic identities. The system serves itself by using its own molecular structure as the identification key.
3Reliability
If distributed ledger technology is implemented for tracking, then security and accuracy of tracking are improved, but system complexity and implementation cost increase
Solution Approach 1:
The patent establishes the molecular sequence as the therapeutic's identity before the therapeutic enters the supply chain. This preliminary tagging with an intrinsic molecular fingerprint ensures that identification is built-in from the start, eliminating the need for complex label application processes later. The blockchain ledger is also prepared in advance with the molecular sequences, creating a ready framework for automatic verification.
Data Source
AI summary
An autonomous tracking system receives a request to administer a patient-specific therapeutic comprising a scanned identifier associated with a labeled dual chamber device (DCD) including a first chamber having one or more lyophilized components, a second chamber having a reconstitution buffer, and a locking mechanism for controlling access to the DCD chambers. A tracking engine queries an administration database based on the scanned identifier to find a notarized ledger associated with the DCD and retrieves a blockchain entry comprising a first distributed ledger transaction identifying the one or more lyophilized components and a digital token associated with an owner of the labeled DCD. After the owner is authenticated, a second distributed transaction is created identifying the one or more lyophilized components as being authorized for administration to the patient. In response, autonomous access to the one or more lyophilized components unlocks the locking mechanism to administer the medication.